LSD vs MDMA

Comparing LSD vs MDMA means comparing two drugs that share a Schedule I classification but almost nothing else — different mechanisms, different target conditions, and, as of 2026, very different FDA trial trajectories. This guide compares them side by side.

Quick answer: LSD vs MDMA

LSD and MDMA are not interchangeable "psychedelics" — MDMA is not a classic serotonergic psychedelic at all. LSD produces strong visual and perceptual changes over 8 to 12 hours through the 5-HT_2A receptor; MDMA produces elevated mood and reduced fear response over an 8-hour supervised session through a serotonin/dopamine/norepinephrine release mechanism, with no LSD-style visual effects. Neither has any state-level legal access in the US. LSD's pharmaceutical program (DT120) is further along in FDA trials than MDMA's, whose first NDA was rejected in 2024 and has since been resubmitted.

LSD vs MDMA: side-by-side comparison

How LSD and MDMA work

LSD is a partial agonist at the 5-HT_2A serotonin receptor — the same core mechanism shared with psilocybin and DMT — which is why it is grouped with those drugs as a "classic psychedelic" and produces the perceptual and visual changes associated with that category.

MDMA works differently. It is not a classic serotonergic psychedelic: it does not primarily act at the 5-HT_2A receptor and does not produce the visual imagery or ego-dissolution effects LSD does. Instead it is classified as an entactogen or empathogen — it triggers a release of serotonin, dopamine, and norepinephrine that reliably produces elevated mood, increased interpersonal trust, and a reduced fear response. That fear-response reduction is specifically why MDMA is studied for PTSD, a disorder defined by a chronically over-active fear response that makes exposure-based therapy difficult to tolerate.

Read our full LSD guide and MDMA guide for the pharmacology and research history of each in more depth.

Duration and the experience

An LSD session runs 8 to 12 hours: onset within 30 to 90 minutes, a plateau over 4 to 6 hours, and a slow return to baseline. The experience is a sustained, gradually-building intensity rather than a sharp peak.

MDMA is structured differently in the Phase 3 protocol used by Resilient Pharmaceuticals (formerly Lykos/MAPS): each supervised dosing session runs 8 hours, with one male and one female co-therapist present throughout, an initial 120–180 mg dose, and an optional supplemental half-dose roughly 90 minutes in. That 8-hour figure is the length of the supervised clinical session — including monitoring before and after peak effects — not a claim about the raw pharmacological duration of MDMA outside a supervised setting.

Clinical trial status

LSD's modern drug-development program is currently further along than MDMA's. Definium Therapeutics (formerly MindMed) developed DT120, an orally disintegrating tablet form of LSD tartrate that holds FDA Breakthrough Therapy Designation for generalized anxiety disorder. By August 2026, both of its Phase 3 trials that had read out, Voyage (anxiety) and Emerge (depression), reported positive topline results. Panorama, the confirmatory anxiety trial, is still pending.

MDMA's path has been rockier. In August 2024, the FDA issued a Complete Response Letter (CRL) declining to approve midomafetamine (MDMA) capsules for PTSD, citing functional unblinding (participants could usually tell whether they'd received MDMA or placebo), trial-conduct concerns, unresolved questions about how long the benefit lasts, and incomplete cardiac safety and lab data.¹ In October 2024, Lykos accepted that the path forward required a fresh Phase 3 trial. In August 2026, now renamed Resilient Pharmaceuticals, the company resubmitted the NDA — branded Rysanso if approved — without running that additional Phase 3 trial. The resubmission instead leans on outside VA follow-up data, a new 32-person Phase I safety study (cardiac and QT-interval monitoring), and an audit addressing the original trial's protocol violations. The FDA has not indicated whether this resolves its 2024 concerns.

Legal status: what actually differs

Both LSD and MDMA are Schedule I at the federal level — no accepted medical use, no prescription path in the US today. Unlike the LSD/DMT comparison, where DMT has real state and religious-exemption access LSD lacks, LSD and MDMA are much closer to each other on US legal access: neither has any state-level decriminalization or exemption anywhere. Colorado's Natural Medicine Health Act (Prop 122) decriminalizes personal possession of psilocybin, DMT, ibogaine, and mescaline for adults 21+ — it does not include LSD or MDMA, and both remain fully criminalized in Colorado as everywhere else in the US.

The real difference shows up outside the US. Australia's Therapeutic Goods Administration has allowed authorised prescribers to prescribe MDMA for PTSD on an individual-patient basis since July 2023 — the only country with an actual MDMA prescribing pathway. LSD has no comparable program anywhere; Switzerland's narrow compassionate-use scheme has authorized a small number of individual, physician-led LSD-assisted cases since 2014, which is closer in spirit to Australia's model but on a much smaller scale and without a formal prescribing framework. For the country-by-country and state-by-state detail behind each drug, see where MDMA is legal and the legal status by state tool.

The verdict: LSD vs MDMA — which matters for you?

Follow LSD's program if you are tracking anxiety or depression drug development. DT120's two positive Phase 3 readouts put it closer to a future FDA-approved medicine for those conditions than MDMA's currently is, but enrollment in a clinical trial remains the only legal way to access it.

Follow MDMA's program if you are tracking PTSD treatment specifically, or if you are in Australia and PTSD-eligible, where an authorised prescriber can legally prescribe it today — the only real-world prescribing access either drug in this comparison currently has anywhere.

For the closely related question of how LSD compares to a psychedelic with real state-level access in the US, see our LSD vs DMT guide, or take our which psychedelic quiz for a personalized starting point. To search open studies for either drug, use our clinical trial finder.